RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a $31 price target.
July 30, 2024 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on NewAmsterdam Pharma and maintained a $31 price target.
The reiteration of an Outperform rating and the maintenance of a $31 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100